# US 2020/0390859 A1 · Methods for treatment of bile acid-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390859 A1
- Document ID: US20200390859A1
- Status: Published application
- Kind: A1
- Application number: 16/917,284
- Filed: 2020-06-30
- Published: 2020-12-17
- Earliest claimed: 2015-11-09
- Assignees: NGM Biopharmaceuticals, Inc.
- Applicants: NGM Biopharmaceuticals, Inc.
- Inventors: Lei Ling; Jian Luo; Hui Tian
- Web page: https://patentgrep.com/patent/US20200390859A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07K 14/50: Fibroblast growth factor [FGF]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.

## Claims

### Claim at position 1

-76. (canceled)

### Claim 77

A method of preventing the induction or exacerbation of pruritus associated with non-alcoholic steatohepatitis (NASH) in a subject being treated for NASH, comprising administering to the subject an effective amount of a peptide, wherein the peptide comprises:
(SEQ ID NO: 70)
MRDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA
HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEI
RPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP
EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (M70).

### Claim 78 (depends on 77)

The method of claim 77, wherein the peptide consists of SEQ ID NO:70.

### Claim 79 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 0.3 mg.

### Claim 80 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 1 mg.

### Claim 81 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 2 mg.

### Claim 82 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 3 mg.

### Claim 83 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 5 mg.

### Claim 84 (depends on 77)

The method of claim 77, wherein the effective amount of the peptide is 10 mg.

### Claim 85 (depends on 77)

The method of claim 77, wherein the peptide is for administration once a day.

### Claim 86 (depends on 77)

The method of claim 77, wherein the peptide is for administration twice a day.

### Claim 87 (depends on 77)

The method of claim 77, wherein the peptide is for subcutaneous administration.

### Claim 88 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 7 days or longer.

### Claim 89 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 14 days or longer.

### Claim 90 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 21 days or longer.

### Claim 91 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 28 days or longer.

### Claim 92 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 1 to 12 months.

### Claim 93 (depends on 77)

The method of claim 77, wherein the peptide is for administration for 12 months.

### Claim 94 (depends on 77)

The method of claim 77, wherein the peptide is for administration for more than 12 months.

### Claim 95 (depends on 77)

The method of claim 77, wherein the peptide is administered in combination with ursodeoxycholic acid (UDCA).

### Claim 96 (depends on 77)

The method of claim 77, wherein the subject is a human.
